Mulcahy Elizabeth Q X, Zhang Ying, Colόn Rossymar R, Cain Shelby R, Gibert Myron K, Dube Collin J, Hafner Markus, Abounader Roger
Department of Microbiology, Immunology & Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA.
National Institutes of Health (NIH), Bethesda, MD 20894, USA.
Int J Mol Sci. 2022 Apr 1;23(7):3930. doi: 10.3390/ijms23073930.
Glioblastoma (GBM) is the most frequent and lethal primary malignant brain tumor. Despite decades of research, therapeutic advances that significantly prolong life are non-existent. In recent years, microRNAs (miRNAs) have been a focus of study in the pathobiology of cancer because of their ability to simultaneously regulate multiple genes. The aim of this study was to determine the functional and mechanistic effects of miR-3928 in GBM both in vitro and in vivo. To the best of our knowledge, this is the first article investigating the role of miR-3928 in GBM. We measured endogenous miR-3928 expression levels in a panel of patient-derived GBM tissue samples and cell lines. We found that GBM tissue samples and cell lines express lower levels of miR-3928 than normal brain cortex and astrocytes, respectively. Therefore, we hypothesized that miR-3928 is a tumor suppressive microRNA. We verified this hypothesis by showing that exogenous expression of miR-3928 has a strong inhibitory effect on both cell growth and invasiveness of GBM cells. Stable ex vivo overexpression of miR-3928 in GBM cells led to a reduction in tumor size in nude mice xenografts. We identified many targets (MDM2, CD44, DDX3X, HMGA2, CCND1, BRAF, ATOH8, and BMI1) of miR-3928. Interestingly, inhibition of the oncogene MDM2 also led to an upregulation of wild-type p53 expression and phosphorylation. In conclusion, we find that miR-3928, through the downregulation of several oncogenes and upregulation and activation of wild-type p53, is a strong tumor suppressor in GBM. Furthermore, the fact that miR-3928 can target many important dysregulated proteins in GBM suggests it might be a "master" regulatory microRNA that could be therapeutically exploited.
胶质母细胞瘤(GBM)是最常见且致命的原发性恶性脑肿瘤。尽管经过了数十年的研究,但仍不存在能显著延长生命的治疗进展。近年来,微小RNA(miRNA)因其能够同时调节多个基因,已成为癌症病理生物学研究的焦点。本研究的目的是在体外和体内确定miR - 3928在GBM中的功能和作用机制。据我们所知,这是首篇研究miR - 3928在GBM中作用的文章。我们检测了一组源自患者的GBM组织样本和细胞系中内源性miR - 3928的表达水平。我们发现,GBM组织样本和细胞系中miR - 3928的表达水平分别低于正常脑皮质和星形胶质细胞。因此,我们推测miR - 3928是一种肿瘤抑制性微小RNA。我们通过证明miR - 3928的外源性表达对GBM细胞的生长和侵袭性均有强烈抑制作用,验证了这一假设。miR - 3928在GBM细胞中的稳定体外过表达导致裸鼠异种移植瘤的肿瘤大小减小。我们鉴定出了miR - 3928的许多靶标(MDM2、CD44、DDX3X、HMGA2、CCND1、BRAF、ATOH8和BMI1)。有趣的是,对癌基因MDM2的抑制也导致野生型p53表达和磷酸化上调。总之,我们发现miR - 3928通过下调多个癌基因以及上调和激活野生型p53,在GBM中是一种强大的肿瘤抑制因子。此外,miR - 3928能够靶向GBM中许多重要的失调蛋白这一事实表明,它可能是一种可用于治疗的“主”调节性微小RNA。